UnitedHealth delivered a strong second-quarter beat and raised guidance, but shares gave back gains; Deutsche Bank maintains Hold

Overview

This report is Deutsche Bank's company update on UnitedHealth Group's second-quarter 2026 results and guidance update. The core judgment is that UNH's second-quarter performance covered nearly all the improvements investors wanted to see, including a strong earnings beat, improved full-year EPS and MLR guidance, Medicare Advantage trends better than previously feared, a clearer OptumHealth recovery, and stronger cash flow and buyback capacity. Even so, the stock retreated from an opening gain of about 9% to close up only about 1%, showing that the market remains cautious on the MCO sector and UNH's recovery pace.

Core views

Deutsche Bank maintains Hold, with the core reason not being inadequate results but that near-term positives have already been fairly well reflected in the stock price. The report believes 2026 adjusted EPS guidance of $19.50-20.00 can become the new baseline for 2027 growth, and management also reiterated its long-term 13%-16% EPS growth algorithm. At the same time, Commercial business cost trends remain stubbornly high, while factors including the No Surprises Act independent dispute resolution process, medical service intensity, provider coding intensity, drug costs, and GLP-1 continue to pressure margins. Deutsche Bank views Commercial as the main current blemish, but also as a potential upside lever for future recovery through pricing, cost efficiency, AI-driven anti-fraud/waste/abuse, and medical cost management.

Analysis framework

The report combines earnings comparison, guidance updates, segment operating trends, and valuation roll-forward: it first compares Q2 revenue, EPS, MLR, cash flow, and membership data against Deutsche Bank estimates and market consensus; it then breaks down the operating performance of UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx; finally, it rolls the valuation basis forward to 2027 EPS and derives the $467 target price using 20x estimated 2027 EPS.

Methodology notes

• equity_researchearnings_beat_and_raise

  Earnings beat and guidance raise

  By comparing actual revenue, EPS, MLR, and cash flow with prior expectations, the report judges whether the company's fundamentals exceeded market expectations and assesses whether the new guidance raises the earnings baseline for subsequent years.

• Valuation methodsforward_pe

  Forward P/E valuation

  Deutsche Bank rolls the valuation basis forward to 2027 EPS and uses about 20x estimated 2027 EPS to derive the $467 target price.

• managed_caremedical_loss_ratio_analysis

  MLR medical loss ratio analysis

  The report focuses on consolidated MLR, Medicare trends, Commercial cost trends, and reserve quality to judge the credibility of margin recovery in managed care.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• UnitedHealth Group (UNH.N / UNH US)

  Primary covered company and rating target in the report

  Strengths

  Second-quarter revenue, EPS, and MLR all beat expectations; 2026 EPS guidance was raised; cash flow and buyback capacity improved; OptumHealth's recovery path is clearer.

  Weaknesses

  Commercial cost trends remain elevated, delaying full margin recovery; the stock's reaction to positive news was limited; the MCO sector remains under pressure overall.

  Comparison

  Versus market consensus, Q2 revenue of $112.0B was above $110.6B, adjusted EPS of $6.38 was above $4.89, and 2026 EPS guidance was also above the consensus expectation of $18.49.

  Risks

  Deteriorating medical costs, weaker-than-expected execution on pricing and member exits, federal and state regulatory changes, managed care pricing competition, DOJ investigation impact, and drug pricing/PBM reform.

• OptumHealth

  A key growth and margin recovery business under UNH

  Strengths

  Improved care management, operating discipline, and payer coordination, with the margin recovery path advancing from slightly above 2% in 2026 toward about 4% in 2027 and a 6% target in 2028.

  Weaknesses

  Still in the recovery phase, with current margins still below the long-term target.

  Comparison

  The report describes it as the standout part of Optum.

  Risks

  Slower-than-expected recovery, insufficient execution in medical cost management, and weaker payer coordination.

• Commercial business

  UNH's main current source of pressure and a potential future recovery lever

  Strengths

  If pricing, administrative efficiency, AI-driven anti-fraud/waste/abuse, and medical cost management improve, there is future upside potential.

  Weaknesses

  Cost trends remain stubbornly elevated and slightly above the prior expectation of about 11%, with full recovery delayed until after 2027.

  Comparison

  Compared with improvements in Medicare and Optum, Commercial is the main blemish highlighted in the report.

  Risks

  Continued pressure from the No Surprises Act dispute resolution process, provider coding intensity, service intensity, specialty drugs, and GLP-1-related drug costs.

Key data

• Q2 total revenue112.0B USDAbove Deutsche Bank's estimate of $110.0B and the market expectation of $110.6B.
• Q2 adjusted EPS6.38 USDAbove Deutsche Bank's estimate of $4.73 and the market expectation of $4.89.
• 2026 adjusted EPS guidance19.50-20.00 USDThe midpoint was raised by about $1.50, mainly reflecting an about $1.49 beat in the second quarter.
• Consolidated MLR86.7%170 basis points better than market expectations; the midpoint of full-year MLR guidance was lowered by about 70 basis points to around 88.1% ±25 basis points.
• Operating cash flow guidance24B USDThe company raised CFO guidance from $18B to $24B.
• Share repurchase target5B+ USDThe company doubled its share repurchase target to more than $5 billion.
• Target price467.00 USDRaised from $370 to $467, corresponding to about 20x estimated 2027 EPS.
• RatingHoldDeutsche Bank maintains a neutral rating.

Impact & implications

In terms of investment implications, the report reinforces the credibility of a bottoming and recovery in UNH fundamentals: Medicare Advantage trends came in below the initial expectation of about 10%, OptumHealth recovered faster than expected, OptumInsight is beginning to show AI-driven operating and product momentum, and improved cash flow enhances capital allocation flexibility. However, the rating remains at Hold, indicating that Deutsche Bank believes the current share price has already absorbed a meaningful portion of the earnings beat, and that more convincing re-rating logic would require clearer easing in Commercial cost trends, sustained delivery of margin recovery, and further reduction in regulatory/investigation risks.

Risks

• Further deterioration in medical cost trends.
• The company may fail to achieve prudent pricing and plan exits.
• Healthcare regulatory changes at the federal and state levels.
• Intensifying pricing competition in the managed care industry.
• Potential impact from the reported DOJ investigation.
• Drug pricing and PBM reform risks.
• Commercial margin recovery slower than expected.

What to watch

• Whether 2026 EPS can approach or exceed the high end of the $19.50-20.00 guidance range.
• Whether Commercial cost trends and margin recovery show a clear inflection point.
• Whether Medicare Advantage member retention, trends, and margins continue to come in better than expected.
• Whether OptumHealth margins can improve from slightly above 2% in 2026 toward about 4% in 2027.
• Whether OptumInsight's AI-driven operating and product momentum can translate into sustained revenue and profit growth.
• Actual execution of operating cash flow and the more than $5 billion buyback plan.
• Marginal changes in regulation, the DOJ investigation, PBM reform, and industry pricing competition.